Silencing the ZDHHC20 gene reduces PI3K-AKT signalling and MYC expression while increasing sensitivity of tumour cells to PI3K inhibitors, identifying ZDHHC20 inhibition as a potential therapeutic target within the PI3K-AKT axis 44. The gene discussed is AKT1; the disease is neoplasm.